Posted on June 15th, 2011 by Health News
The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor tissue…
Read more
Filed under: Women's Health
Tags: Breast Cancer, cancer, Drug, gene, Genetic, Tumor, Women's Health
Related posts
- New Drug Reduces Tumor Size In Women With Advanced Hereditary Ovarian Or Breast Cancer (0)
Weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations...
Read more
[tags] Women's Health [/tags]
- FDA Approves New Test To Help Determine If Breast Cancer Patients Are Candidates For Herceptin Treatment (0)
The U.S. Food and Drug Administration approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of [...]
- Vitamin D Relieves Joint, Muscle Pain For Breast Cancer Patients (0)
High-dose vitamin D relieves joint and muscle pain for many breast cancer patients taking estrogen-lowering drugs, according to a new study from Washington University School of Medicine in St. Louis. The drugs, known as aromatase inhibitors, are commonly prescribed to shrink breast tumors fueled by the hormone estrogen and help prevent cancer recurrence...
Read more
[tags] Women's [...]
- Study finds Olaparib can reduce tumor size in ovarian cancer women (0)
Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.
Read [...]
- Mayo Collaboration Finds Source Of Breast Drug Side Effect (0)
Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear in the online issue of Journal of Clinical [...]
Leave a Reply